Drug-Drug Interactions for Therapeutic Biologics (eBook)
378 Seiten
John Wiley & Sons (Verlag)
978-1-118-63021-1 (ISBN)
interaction assessments for therapeutic biologics
Offering both theory and practical guidance, this book fully
explores drug-drug interaction assessments for therapeutic
biologics during the drug development process. It draws together
and analyzes all the latest findings and practices in order to
present our current understanding of the topic and point the way to
new research. Case studies and examples, coupled with expert
advice, enable readers to better understand the complex mechanisms
of biologic drug-drug interactions.
Drug-Drug Interactions for Therapeutic Biologics features
contributions from leading international experts in all areas of
therapeutic biologics drug development and drug-drug interactions.
The authors' contributions reflect a thorough review and analysis
of the literature as well as their own firsthand laboratory
experience. Coverage includes such essential topics as:
* Drug-drug interaction risks in combination with small molecules
and other biologics
* Pharmacokinetic and pharmacodynamic drug-drug interactions
* In vitro methods for drug-drug interaction assessment and
prediction
* Risk-based strategies for evaluating biologic drug-drug
interactions
* Strategies to minimize drug-drug interaction risk and mitigate
toxic interactions
* Key regulations governing drug-drug interaction assessments for
therapeutic biologics.
Drug-Drug Interactions for Therapeutic Biologics is
recommended for pharmaceutical and biotechnology scientists,
clinical pharmacologists, medicinal chemists, and toxicologists. By
enabling these readers to understand how therapeutic biologics may
interact with other drugs, the book will help them develop safer,
more effective therapeutic biologics.
HONGHUI ZHOU, PhD, is Senior Scientific Director and Janssen Fellow, Janssen Research & Development, LLC, Johnson & Johnson, where he heads the Pharmacokinetics & Pharma-codynamics Department within Biologics Clinical Pharmacology. Board-certified by the American Board of Clinical Pharmacology and an American College of Clinical Pharmacology Fellow, Dr. Zhou has authored more than 150 peer-reviewed scientific papers, book chapters, and conference abstracts in pharmacokinetics, pharmacodynamics, and drug-drug interactions. BERND MEIBOHM, PhD, is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center. Dr. Meibohm is a Fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology.
PREFACE ix
ABOUT THE EDITORS xi
CONTRIBUTORS xiii
1. DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS: A JOURNEY JUST
BEGINNING 1
Honghui Zhou and Bernd Meibohm
2. PHARMACOKINETIC AND PHARMACODYNAMIC-BASED DRUG
INTERACTIONS FOR THERAPEUTIC PROTEINS 5
Dan Lu, Sandhya Girish, Frank-Peter Theil, and Amita
Joshi
3. DRUG INTERACTION ASSESSMENT STRATEGIES: SMALL MOLECULES
VERSUS THERAPEUTIC PROTEINS 39
Shannon Dallas, Carlo Sensenhauser, Souvik Chattopadhyay, and
Jose Silva
4. MODEL-INDEPENDENT AND MODEL-BASED METHODS TO ASSESS
DRUG-DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 63
Di Wu and Jeffrey S. Barrett
5. UTILITY OF IN VITRO METHODS IN DRUG-DRUG INTERACTION
ASSESSMENT AND PREDICTION FOR THERAPEUTIC BIOLOGICS 73
Theresa Nguyen, Narendra Kishnani, and Raymond Evers
6. USE OF ANIMAL MODELS FOR PROJECTION OF CLINICAL
DRUG-DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 103
Eugenia Kraynov and Martin E. Dowty
7. THE COCKTAIL APPROACH AND ITS UTILITY IN DRUG-DRUG
INTERACTION ASSESSMENTS FOR THERAPEUTIC PROTEINS 111
Alexander Jetter and Uwe Fuhr
8. LOGISTIC CONSIDERATIONS IN STUDY DESIGN FOR BIOLOGIC
DRUG-DRUG INTERACTION ASSESSMENTS 119
Min Zhu and Yu-Nien (Tom) Sun
9. STATISTICAL CONSIDERATIONS IN ASSESSING DRUG-DRUG
INTERACTIONS FOR THERAPEUTIC BIOLOGICS 139
Chuanpu Hu and Honghui Zhou
10. SCIENTIFIC PERSPECTIVES ON THERAPEUTIC PROTEIN
DRUG-DRUG INTERACTION ASSESSMENTS 155
Hong Zhao, Lei Zhang, Kellie Reynolds, and Shiew-Mei
Huang
11. DISEASE-DRUG-DRUG INTERACTION ASSESSMENTS FOR
TOCILIZUMAB--A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-6
RECEPTOR TO TREAT PATIENTS WITH RHEUMATOID ARTHRITIS 191
Xiaoping Zhang and Barbara J. Brennan
12. DRUG-DRUG INTERACTIONS FOR ETANERCEPT--A
FUSION PROTEIN 207
Joan Korth-Bradley
13. DRUG INTERACTIONS OF CYTOKINES AND ANTICYTOKINE
THERAPEUTIC PROTEINS 215
J. Greg Slatter, Larry C. Wienkers, and Leslie J.
Dickmann
14. DRUG INTERACTIONS FOR GROWTH FACTORS AND HORMONES
239
Yow-Ming C. Wang and Tarundeep Kakkar
15. DRUG-DRUG INTERACTIONS FOR NUCLEIC ACID-BASED
DERIVATIVES 257
Jian Wang and Hong Zhao
APPENDIX: MONOGRAPHS FOR DRUG-DRUG INTERACTIONS OF
THERAPEUTICS BIOLOGICS 275
Jocelyn Leu, Simone Kasek, Christine Li, Wararat Limothai, Dora
Babu Madhura, Chetan Rathi, Sumit Rawal, Josiah Ryman, Margaret
Thomson, Ashit Trivedi, Honghui Zhou, and Bernd Meibohm
INDEX 351
Erscheint lt. Verlag | 10.5.2013 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Naturwissenschaften ► Chemie | |
Technik | |
Schlagworte | Biowissenschaften • Chemie • Chemistry • Drug Discovery & Development • Life Sciences • Medical Science • Medizin • Molecular Biology • Molekularbiologie • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung |
ISBN-10 | 1-118-63021-1 / 1118630211 |
ISBN-13 | 978-1-118-63021-1 / 9781118630211 |
Haben Sie eine Frage zum Produkt? |
Größe: 2,2 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich